

North Central Cancer Treatment Group

N0272 Phase I/II Trial of Imatinib Mesylate; (Gleevec; STI571) In Treatment of
Recurrent Oligodendroglioma and Mixed Oligoastrocytoma

Status Change – May 4, 2011

NOTICE OF STATUS CHANGE

The accrual objective for Study 2, Arm B, has been met. Therefore, all arms of the study are now permanently closed to accrual, effective Wednesday, May 4, 2011. Patients currently on study should continue to be followed according to the protocol.

Please retain this notice with the protocol.